Biochemical Markers and Skeletal Metastases

Laurence Demers, Luis Costa, Allan Lipton

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Bisphosphonate therapy for the treatment of skeletal complications from osteolytic metastases has become standard care in patients with cancer who have metastatic bone disease. The ability to assess patient response to bisphosphonate therapy has been helped by the availability of immunoassays that can measure bone collagen breakdown products that are increased in the blood and urine of patients with osteolytic metastases. Measurements of the carboxy and amino terminal telopeptides in blood and urine particularly have been helpful as adjunct methods to facilitate the treatment of patients with skeletal metastases. These biochemical bone markers have been shown to correlate with the extent of skeletal involvement and seem to provide a means of monitoring the dose and scheduling of bisphosphonate therapy of patients with cancer who have bony metastases.

Original languageEnglish (US)
JournalClinical Orthopaedics and Related Research
Issue number415 SUPPL.
DOIs
StatePublished - Jan 1 2003

Fingerprint

Biomarkers
Neoplasm Metastasis
Diphosphonates
Urine
Therapeutics
Bone and Bones
Bone Diseases
Immunoassay
Neoplasms
Patient Care
Collagen

All Science Journal Classification (ASJC) codes

  • Surgery
  • Orthopedics and Sports Medicine

Cite this

@article{997189596e014b2c96b95a5a0ba30257,
title = "Biochemical Markers and Skeletal Metastases",
abstract = "Bisphosphonate therapy for the treatment of skeletal complications from osteolytic metastases has become standard care in patients with cancer who have metastatic bone disease. The ability to assess patient response to bisphosphonate therapy has been helped by the availability of immunoassays that can measure bone collagen breakdown products that are increased in the blood and urine of patients with osteolytic metastases. Measurements of the carboxy and amino terminal telopeptides in blood and urine particularly have been helpful as adjunct methods to facilitate the treatment of patients with skeletal metastases. These biochemical bone markers have been shown to correlate with the extent of skeletal involvement and seem to provide a means of monitoring the dose and scheduling of bisphosphonate therapy of patients with cancer who have bony metastases.",
author = "Laurence Demers and Luis Costa and Allan Lipton",
year = "2003",
month = "1",
day = "1",
doi = "10.1097/01.blo0000092979.12414.54",
language = "English (US)",
journal = "Clinical Orthopaedics and Related Research",
issn = "0009-921X",
publisher = "Springer New York",
number = "415 SUPPL.",

}

Biochemical Markers and Skeletal Metastases. / Demers, Laurence; Costa, Luis; Lipton, Allan.

In: Clinical Orthopaedics and Related Research, No. 415 SUPPL., 01.01.2003.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Biochemical Markers and Skeletal Metastases

AU - Demers, Laurence

AU - Costa, Luis

AU - Lipton, Allan

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Bisphosphonate therapy for the treatment of skeletal complications from osteolytic metastases has become standard care in patients with cancer who have metastatic bone disease. The ability to assess patient response to bisphosphonate therapy has been helped by the availability of immunoassays that can measure bone collagen breakdown products that are increased in the blood and urine of patients with osteolytic metastases. Measurements of the carboxy and amino terminal telopeptides in blood and urine particularly have been helpful as adjunct methods to facilitate the treatment of patients with skeletal metastases. These biochemical bone markers have been shown to correlate with the extent of skeletal involvement and seem to provide a means of monitoring the dose and scheduling of bisphosphonate therapy of patients with cancer who have bony metastases.

AB - Bisphosphonate therapy for the treatment of skeletal complications from osteolytic metastases has become standard care in patients with cancer who have metastatic bone disease. The ability to assess patient response to bisphosphonate therapy has been helped by the availability of immunoassays that can measure bone collagen breakdown products that are increased in the blood and urine of patients with osteolytic metastases. Measurements of the carboxy and amino terminal telopeptides in blood and urine particularly have been helpful as adjunct methods to facilitate the treatment of patients with skeletal metastases. These biochemical bone markers have been shown to correlate with the extent of skeletal involvement and seem to provide a means of monitoring the dose and scheduling of bisphosphonate therapy of patients with cancer who have bony metastases.

UR - http://www.scopus.com/inward/record.url?scp=0142250328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142250328&partnerID=8YFLogxK

U2 - 10.1097/01.blo0000092979.12414.54

DO - 10.1097/01.blo0000092979.12414.54

M3 - Article

JO - Clinical Orthopaedics and Related Research

JF - Clinical Orthopaedics and Related Research

SN - 0009-921X

IS - 415 SUPPL.

ER -